

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



AK MEDICAL HOLDINGS LIMITED

愛康醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1789)

CHANGE OF DIRECTORS

The Board hereby announces the following changes:

1. Mr. Eric Wang will retire as an independent non-executive Director with effect from the date of conclusion of the 2024 AGM; and
2. subject to the approval of the Company's shareholders at the 2024 AGM, Mr. Gao Wei will be appointed as an independent non-executive Director with effect from the date of conclusion of the 2024 AGM.

RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board hereby announces that Mr. Eric Wang, who is subject to retirement by rotation in the 2024 AGM pursuant to the Articles, will retire as an independent non-executive Director with effect from the date of conclusion of the 2024 AGM due to his desire to devote more time to his other business commitments.

Mr. Eric Wang has confirmed that he has no disagreement with the Board and there is no matter relating to his retirement that needs to be brought to the attention of the Stock Exchange and/or the shareholders of the Company.

The Board would like to take this opportunity to express its gratitude to Mr. Eric Wang for his invaluable contribution to the Company during his tenure of office.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Gao Wei (高偉) (“**Mr. Gao**”) will be appointed as an independent non-executive Director with effect from the date of conclusion of the 2024 AGM, subject to the approval of the Company's shareholders at the 2024 AGM.

Mr. Gao, aged 57, is currently the Chief Representative of Beijing Representative Office of the Hong Kong Chartered Governance Institute (formerly known as the Hong Kong Institute of Chartered Secretaries), and has extensive experience in corporate financing and managing overseas-listed companies. Mr. Gao now serves as the company secretary of Zhongguancun Science-tech Leasing Co., Ltd. (中關村科技租賃股份有限公司), the H shares of which are listed on the Main Board of the Stock Exchange (stock code: 1601.HK), and an independent non-executive director of Guolian Securities Co., Ltd., (國聯證券股份有限公司), the H shares of which are listed on the Main Board of the Stock Exchange (stock code: 1456.HK) and the A shares of which are listed on the Shanghai Stock Exchange (stock code: 601456.SH). He also serves as an independent non-executive director of Best Mart 360 Holdings Limited, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 2360.HK). He first joined the Council of the Hong Kong Chartered Governance Institute in 2013 and served as a vice-president from 2014 to 2020 and 2022 to 2023. He served as one of the vice chairman of the board secretary committee of China Association of Public Companies (中國上市公司協會) from November 2015 to November 2018. He served as a director of Sinotrans Air Transportation Development Co., Ltd. (中外運空運發展股份有限公司), a company previously listed on Shanghai Stock Exchange (stock code: 600270.SH) from November 2011 to June 2019 and the general manager of the company from January 2016 to June 2019, primarily responsible for overall operation and management, and he served as the legal representative of the company from January 2017 to August 2019. He served as the board secretary and company secretary of Sinotrans Limited (中國外運股份有限公司), a company listed on the Stock Exchange (stock code: 0598.HK) from January 2003 to December 2016, primarily responsible for secretarial work; he served as the general counsel of Sinotrans Limited from January 2010 to June 2019, primarily responsible for legal affairs.

Mr. Gao obtained a bachelor's degree in management engineering from University of Science and Technology Beijing (北京科技大學) in July 1989, and further obtained a master's degree in economics from Central University of Finance and Economics (中央財經大學) in January 1993. He obtained a doctor's degree in law from University of International Business and Economics (對外經濟貿易大學) in June 1999. Mr. Gao was accredited as a PRC lawyer by the Ministry of Justice of the People's Republic of China in October 1996. He is a fellow member of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Mr. Gao is also an arbitrator of each of China International Economic and Trade Arbitration Commission, China Maritime Arbitration Commission, Beijing Arbitration Commission and Shanghai Arbitration Commission.

Pursuant to the letter of appointment issued by the Company to Mr. Gao, subject to the approval of the Company's shareholders at the 2024 AGM, his initial term of office is three years commencing from the date of conclusion of the 2024 AGM, and he will be subject to retirement by rotation and re-election at least once every three years in accordance with the Articles. According to the terms of Mr. Gao's appointment letter, Mr. Gao is entitled to receive an annual Director's fee of RMB180,000, which has been recommended by the remuneration committee and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

Save as disclosed above, Mr. Gao has confirmed that he does not hold (i) any other position with the Company or other members of the Group; (ii) any directorship in any other public companies with securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (iii) any other major appointments and professional qualifications.

As far as the Directors are aware, as at the date of this announcement, Mr. Gao has confirmed that he did not have any other relationship with any Director, senior management or substantial shareholder or controlling shareholders of the Company, or any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, there is no other information that is required to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules nor are there any other matters that need to be brought to the attention of the shareholders of the Company relating to Mr. Gao's appointment. Mr. Gao has confirmed that (i) he meets the independent criteria as set out in Rule 3.13 of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

The Board would like to express its warmest welcome to Mr. Gao on his appointment.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meanings:

“2024 AGM”	the forthcoming annual general meeting of the Company currently scheduled to be held in or around June 2024
“Articles”	the third amended and restated memorandum and articles of association of the Company (and as amended from time to time)
“Board”	the board of Directors
“Company”	AK Medical Holdings Limited (stock code: 1789), a company incorporated in the Cayman Islands with limited liability and whose Shares are listed and traded on the Main Board of the Stock Exchange
“Director(s)”	the directors of the Company
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the People's Republic of China

“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“RMB”	Renminbi, the lawful currency of the People’s Republic of China
“Share(s)”	ordinary share(s) of HK\$0.01 each in the share capital of the Company
“Stock Exchange”	The Stock Exchange of Hong Kong Limited

By Order of the Board
AK Medical Holdings Limited
Li Zhijiang
Chairman

Hong Kong, 18 April 2024

As at the date of this announcement, the Board comprises Mr. Li Zhijiang, Ms. Zhang Bin, Mr. Zhang Chaoyang and Ms. Zhao Xiaohong as executive Directors, Dr. Wang David Guowei as non-executive Director, and Mr. Kong Chi Mo, Dr. Li Shu Wing David and Mr. Eric Wang as independent non-executive Directors.